Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus physician's choice treatment for pretreated HER2-negative breast cancer
ChiCTR1900025659Phase 4Recruiting
- Sponsor
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment
- Start
- Sep 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in breast cancer, sponsored by Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment. Primary endpoint: objective response rate. Started Sep 2019; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900025659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025659.